WALTHAM, Mass.--(BUSINESS WIRE)--
Corindus
Vascular Robotics, Inc. (NYSE MKT: CVRS), a leading developer of
precision vascular robotics, today announced the appointment of Jeff
Lemaster as Chief Commercial Officer.
Mr. Lemaster brings 20 years of commercial sales and marketing
experience in the cardiovascular medical device industry to Corindus and
has extensive global new product launch experience in the areas of
interventional cardiology and peripheral. He most recently served as
Global Vice President, Marketing of C.R. Bard, Inc. (NYSE: BCR), a
leading multinational developer, manufacturer and marketer of
innovative, life-enhancing medical technologies. He has a proven track
record of commercial success having held senior sales and marketing
leadership positions at C.R. Bard, ACIST Medical Systems and Boston
Scientific Corporation (NYSE: BSX).
As Chief Commercial Officer at Corindus, Mr. Lemaster will lead and
execute revenue and commercial strategy to drive growth and market
adoption globally.
"I am delighted to welcome Jeff to Corindus, and we look forward to his
future contributions. His extensive commercial experience, particularly
in the interventional and peripheral arena, will enable us to build and
sustain strong robotic programs that benefit our customers and their
patients," said Corindus CEO, Mark J. Toland.
"I look forward to working with the Corindus team and the broader
interventional community to build robotic programs that transform the
way we treat patients while protecting cath lab teams," said Mr.
Lemaster.
About Corindus Vascular Robotics
Corindus
Vascular Robotics, Inc. is a global technology leader in
robotic-assisted vascular interventions. The company's CorPath®
System is the first FDA-cleared medical device to bring robotic
precision to both percutaneous coronary intervention (PCI) and
peripheral vascular intervention. During the procedure, the
interventional cardiologist sits at a radiation-shielded workstation to
advance stents and guidewires with millimeter-by-millimeter precision.
The workstation allows the physician greater control and the freedom
from wearing heavy lead protective equipment that causes musculoskeletal
injuries. With the CorPath System, Corindus Vascular Robotics brings
robotic precision to complex, radial, coronary and peripheral procedures
to help optimize clinical outcomes and minimize the costs associated
with complications of improper stent placement with manual procedures.
Corindus stands behind its product with its unique $1,000 hospital
credit "One Stent Program." For additional information, visit www.corindus.com,
and follow @CorindusInc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161020005061/en/
